The Miami Stem Cell Therapy Podcast

Ep 37 How Labs Reduce Costs by Increasing Cell Passages

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- Today we’re taking a closer look at a topic that doesn’t usually come up in patient consultations, but plays a meaningful role in how regenerative treatments are developed and priced. That’s the concept of cell passage—and how increasing cell passages can reduce costs, while also influencing how cells behave. If you’ve explored regenerative therapies, you’ve likely heard numbers tied to treatment. Fifty million cells. One hundred million cells. Sometimes more. Those numbers can feel like a clear indicator of strength or effectiveness. But what’s often not discussed is how those cells were expanded before they were ever used. Cell passage refers to the number of times cells have been grown and re-cultured in a laboratory environment. It starts with an initial population—what’s often called passage zero. As those cells multiply, they’re divided and transferred into new culture environments. That becomes passage one. Then passage two. And the process continues. Each passage increases the total number of cells. And from a production standpoint, this is where cost efficiency begins to take shape. Because the more times cells are expanded, the more volume a lab can generate from a single starting sample. That means more doses can be produced without needing additional source material. Over time, this reduces the cost per unit, and allows treatments to be offered at different price points. So when you see higher cell counts associated with a therapy, part of what you’re seeing is the result of this expansion process. But there’s another side to it. As cells go through repeated passages, they don’t just increase in number—they also experience gradual biological changes. These changes aren’t abrupt, and they don’t render cells ineffective, but they can influence how those cells respond once introduced into the body. Over time, cells in culture may become less responsive to signaling cues. Their ability to adapt to a new environment may shift. Their overall behavior can begin to reflect the lab conditions they’ve been grown in, rather than the original tissue they came from. This creates a balance that isn’t always visible in treatment discussions. On one hand, higher passage expansion allows for greater volume and lower cost. On the other, earlier passage cells may retain characteristics that are closer to their original biological state. So the question becomes less about how many cells are being delivered, and more about how those cells are expected to function. Different treatment goals place different demands on cell behavior. In some cases, the primary objective is signaling—helping to influence inflammation or communicate with surrounding tissue. In those scenarios, higher passage cells may still contribute meaningfully. In other cases, the goal involves more direct interaction with tissue. This might include responding to localized damage, adapting to a specific environment, or participating in longer-term repair processes. In those contexts, the functional characteristics of the cells can become more relevant than the total number alone. This is especially true in joint, spine, and musculo-skeletal applications, where treatments are often delivered with a high degree of precision. In many of these procedures, image-guided techniques such as ultrasound or fluoroscopy are used to place cells directly into the area of concern. When delivery is highly targeted, the behavior of the cells at that specific location becomes a central part of the treatment design. That level of precision can shift the conversation even further away from volume, and toward how cells respond once they’re in place. It’s also worth noting that cell passage is not typically highlighted in patient-facing materials. Most discussions focus on metrics that are easier to communicate—like total cell count. While those numbers provide a reference point, they don’t capture how the cells were expanded or how many passages they’ve undergone. And that’s where some of the confusion in the market comes from. Two treatments may present similar cell counts, but the underlying production methods—and therefore the biological profiles—may differ. This doesn’t mean that one approach is automatically better than another. It means that production methods influence how cells behave, and that behavior should align with the goals of the treatment. From a broader perspective, increasing cell passages is a practical solution for scaling regenerative therapies. It allows laboratories to operate efficiently, maintain supply, and manage costs in a way that supports wider access. At the same time, it introduces variables that are worth understanding—especially for patients comparing options. The takeaway here is not that higher passage is good or bad. It’s that cell passage is part of the biological story, not just a manufacturing detail. When evaluating a treatment, it can be helpful to look beyond the headline numbers and consider how the therapy is designed. What is it trying to accomplish? How are the cells expected to behave? And how does the production process support that goal? In regenerative medicine, those questions often matter more than the total count alone. Ultimately, effective treatment planning is less about maximizing inputs and more about matching the right biologic approach to the right condition.   Disclaimer The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs. Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration. Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment. © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 36 Do You Need Exosomes If You’re Already Getting MUSE Stem Cells?

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565. ------------- Today we’re digging into a question that’s coming up more often in regenerative medicine conversations: Do you need exosomes if you’re already getting MUSE stem cells? On the surface, this can sound like a simple add-on decision. But when you step into the biology behind it, the answer becomes more about mechanism than menu options. Let’s start by grounding the difference. MUSE cells—short for multilineage-differentiating stress-enduring cells—are a specific subset of mysynchemal stem cells. What makes them distinct is their ability to survive in difficult environments, respond to tissue damage, and integrate into the body in a controlled way. They don’t just signal repair—they participate in it. Exosomes, on the other hand, are not cells. They’re microscopic vesicles released by cells. You can think of them as carriers of information. They move proteins, RNA, and signaling molecules from one cell to another, influencing how nearby cells behave. So right away, we’re talking about two different levels of biology. One is a living system. The other is a communication tool used by that system. Here’s where things start to overlap—and where confusion tends to happen. MUSE cells naturally produce exosomes. That’s a key point. When MUSE cells are introduced into a treatment area, they don’t just sit there. They respond to the environment. They release signaling molecules. And part of that process includes generating exosomes in real time, based on what the tissue actually needs. So when someone asks, “Should I add exosomes to my MUSE cell treatment?” the first layer of the answer is this: you’re already getting exosome activity as part of the cellular function. That raises a logical follow-up question—when would additional exosomes actually matter? There are scenarios where exosomes can play a supportive role. Not as a replacement, but as a kind of amplifier or primer. For example, if the tissue environment is highly inflamed, or if healing capacity is compromised, exosomes may help shift that environment before or during treatment. They can influence inflammation, support signaling pathways, and potentially make the area more receptive to cellular activity. In that sense, exosomes can be used to prepare the ground. There are also cases where timing becomes important. If exosomes are used before a procedure, they may help modulate inflammation and improve the local environment. If they’re used during the procedure, they can provide immediate signaling support alongside the cells. And if they’re used after, they may help reinforce ongoing repair processes. But none of that means they are always necessary. In many localized treatments—especially when MUSE cells are delivered precisely into a joint or a specific tissue structure—the cells themselves are already doing multiple jobs. They’re responding to damage, adapting to the environment, and producing signaling molecules as needed. In those cases, adding exosomes may not significantly change the outcome. And this is where the conversation shifts from products to protocols. One of the more common issues in regenerative medicine right now is the tendency to bundle therapies together without clearly explaining the role each one plays. More inputs don’t automatically lead to better results. What matters is alignment between the therapy and the condition. MUSE cells and exosomes are not interchangeable. And they’re not automatically additive. They operate in the same ecosystem, but they serve different roles within it. MUSE cells are active participants in repair. Exosomes are part of the communication network that supports that repair. So the real question isn’t, “Should I get both?” It’s, “What does my specific condition require, and how do these tools fit into that?” Another factor that often gets overlooked is how the treatment is delivered. In many MUSE cell protocols, especially for orthopedic or spine-related issues, image guidance is used to place the cells directly into the area of concern. That level of precision can reduce the need for broader systemic signaling support. If the cells are exactly where they need to be, and the environment supports their function, they may be able to carry out their role without additional inputs. On the other hand, in less targeted or more systemic conditions, exosomes may have a different kind of value. So again, context is everything. What this really points to is a larger shift in how we think about regenerative medicine. It’s not about choosing between options on a list. It’s about understanding how different biologic tools behave—and how they interact within the body. MUSE cells represent a dynamic, adaptive approach. Exosomes represent a signaling-based approach. Sometimes those approaches overlap in useful ways. Sometimes they don’t need to. And that distinction matters. Because when treatment decisions are based on mechanism rather than marketing, the conversation becomes a lot more precise. So if you’re evaluating these options, the takeaway is straightforward: MUSE cells already produce exosomes as part of their function. In some cases, adding exosomes may support the process. In others, it may not add meaningful value. The right approach depends on the condition, the environment, and the goals of treatment. Disclaimer The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs. Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration. Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment. © STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

Ep 35 Can Stem Cell Therapy Support Both Pain Relief and Longevity?

Can stem cell therapy support both pain relief and longevity? It’s a question that’s coming up more often as people start to think about health in a broader way. Not long ago, stem cell therapy was mostly discussed in terms of specific problems- joint pain, tendon injuries, or chronic inflammation in one area of the body. Today, patients are asking a bigger question. Can something that helps with pain also support long-term health? To answer that, it helps to break it into two parts. First, what does stem cell therapy actually do for pain? And second, what do we really mean by longevity? In clinical practice, stem cell therapy is primarily used for targeted treatment. That means focusing on a specific area- like a knee, shoulder, or spine. The goal is to reduce inflammation, support tissue repair, and improve function. Biologically, stem cells work through signaling. They release molecules that help regulate inflammation and guide the body’s repair process. Over time, this can lead to improvements in pain and mobility. But it’s not immediate. It’s a gradual process. Now let’s look at longevity. Longevity isn’t just about living longer. It’s about how well the body functions over time- how it recovers, how it handles stress, and how it maintains mobility and independence. So where do these two ideas overlap? One connection is inflammation. Inflammation plays a role in both localized pain and broader aging processes. When you reduce inflammation in a joint, for example, you may also make it easier to stay active. And staying active supports overall health. If pain improves, movement improves. If movement improves, other systems benefit. That’s where stem cell therapy can indirectly support long-term health. But it’s important to be clear. Stem cell therapy is not a direct longevity treatment. And this is where the distinction between targeted and systemic approaches matters. Targeted treatments are designed to address a specific issue. Systemic approaches aim to influence the body more broadly. They’re different strategies, and they serve different purposes. So if you’re asking whether stem cell therapy can do both- relieve pain and support longevity- the most accurate answer is this: It can improve conditions that contribute to long-term health, but it’s not a standalone solution for longevity itself. That’s why your goal matters. Are you trying to reduce pain? Improve function? Or support overall wellness? Each of those requires a different approach. The most useful step is to align your expectations with what the therapy is actually designed to do. Because when that alignment is there, the results tend to make a lot more sense. Stem cell therapy can be a powerful tool for improving how you feel and how you move. And those improvements can absolutely contribute to a healthier, more active life over time. But longevity is a bigger picture. And it’s built from how all those pieces work together.

Ep 34 Are Stem Cells Illegal in the United States?

Are stem cells illegal in the United States? It’s one of the most common questions people ask when they start looking into regenerative medicine. And it makes sense. There’s a lot of mixed information out there. Some sources suggest these treatments are banned. Others make it seem like anything is available if you just look hard enough. The reality is more nuanced. Stem cell therapy is not illegal in the United States. But it is regulated. And understanding that distinction is key to making sense of what’s actually available. In the U.S., stem cell therapies fall under the oversight of the U.S. Food and Drug Administration, or FDA. Their role is to evaluate biologic treatments for safety and to determine how they can be used in clinical settings. But the FDA doesn’t treat all stem cell therapies the same. Instead, they use a framework that separates treatments based on how the cells are sourced, processed, and used. At a high level, there are a few important factors that determine whether a treatment can be offered in a clinic. One is something called minimal manipulation. That refers to how much the cells have been altered outside the body. Another is homologous use. That means the cells are being used for the same basic function they perform naturally. And another factor is whether the cells come from the same patient receiving the treatment. When those criteria are met, certain therapies can be performed under established guidelines. When they’re not, the treatment usually falls into a different category that requires formal FDA approval, often through clinical trials. This is why you’ll sometimes hear terms like “361 therapies” and “351 therapies.” 361 therapies generally involve minimally manipulated cells used in a way that aligns with their natural function. These are the types of treatments more commonly available in clinical practice. 351 therapies involve more complex processing or different intended uses, and they typically require a higher level of regulatory approval before they can be widely offered. So when someone asks whether stem cells are legal, the more accurate answer is this: Some treatments are available within the current regulatory framework, and others are still in the research and approval phase. That brings up another common question. Why are some treatments offered in other countries that aren’t available in the United States? The answer comes down to differences in regulation. Different countries have different standards for approving biologic therapies. Some allow treatments to be introduced more quickly, with fewer requirements for long-term data. Others, like the United States, emphasize a more structured process that includes safety evaluation, evidence gathering, and ongoing monitoring. That approach can slow things down. But it’s designed to ensure that treatments are delivered in a controlled and accountable way. It also helps explain why availability doesn’t always equal advancement. Just because something is offered somewhere doesn’t necessarily mean it has gone through the same level of evaluation. There are also a few misconceptions that tend to come up around this topic. One is the idea that all stem cell treatments require FDA approval before they can be used. That’s not entirely accurate. Some therapies fall within existing guidelines and can be performed without going through a full approval process. Another is the belief that U.S. clinics are limited because they lack access to certain technologies. In most cases, the limitation isn’t capability. It’s compliance with regulatory standards. And then there’s the assumption that regulation prevents innovation. In reality, research in regenerative medicine is ongoing. Many therapies are being studied in clinical trials, and new approaches continue to be developed within the regulatory system. So what should patients take away from all of this? If you’re considering stem cell therapy, it’s important to look beyond general claims and ask specific questions. What type of treatment is being offered? How are the cells sourced and processed? Does the therapy fall within established regulatory guidelines? And what kind of evidence supports its use? These questions help clarify not just what’s available, but how it fits within the broader framework of safety and clinical practice. Because ultimately, the goal of regulation is not to limit access. It’s to ensure that treatments are delivered responsibly, with attention to both safety and outcomes. Stem cell therapy is not illegal in the United States. But it does exist within a system designed to balance innovation with oversight. And understanding that system can make it much easier to navigate your options and make informed decisions about care.

Ep 33 How Long Should a Stem Cell Therapy Clinic Follow You After Treatment?

How Long Should a Stem Cell Therapy Clinic Follow You After Treatment? One of the most overlooked parts of stem cell therapy isn’t the procedure itself. It’s what happens after. When most people think about regenerative medicine, they focus on the treatment. How many cells are used. Where they’re injected. What condition is being treated. But stem cell therapy doesn’t end when the procedure is over. In many ways, that’s where the process actually begins. These treatments work by influencing biological activity over time. Cells signal. They interact with surrounding tissue. They help regulate inflammation and support repair processes. And all of that unfolds gradually. Which is why follow-up care isn’t optional. It’s a core part of the treatment. So the question becomes: how long should a clinic actually follow you after stem cell therapy? The answer is longer than most people expect. Immediately after treatment, the focus is usually on recovery and early response. You might experience some mild inflammation. You may notice subtle changes in pain or mobility. But these early responses don’t tell the whole story. Regenerative therapies are not designed for instant results. They’re designed to support the body’s natural repair mechanisms, which take time. That’s why a structured follow-up plan is important. A typical timeline often starts with an initial check-in somewhere around two to four weeks after the procedure. At that stage, the goal is to assess how the body is responding. Are there any concerns? Are symptoms changing in a meaningful way? From there, follow-up usually continues into the six to twelve week range. This is where you start to see more measurable changes in function. Mobility may improve. Pain levels may shift. Activity tolerance can increase. And then there’s the longer-term evaluation, often three to six months out, or even beyond. This is where the real picture comes into focus. Are the improvements sustained? Is function continuing to improve? Has the treatment meaningfully impacted quality of life? These checkpoints are not arbitrary. They align with how tissue repair actually happens in the body. And without them, it becomes difficult to understand whether a treatment is truly working. But follow-up isn’t just about timing. It’s also about what’s being tracked. Effective follow-up involves structured outcome monitoring. That includes things like pain levels, mobility, and functional performance. It may include how well you’re returning to normal activities. And in some cases, it can involve imaging or additional diagnostics. The goal is to build a complete picture over time. Because without that, you’re left with isolated observations instead of meaningful trends. And that leads to another important point. Not all follow-up protocols are created equal. There are certain red flags patients should be aware of. For example, if a clinic schedules little to no follow-up beyond the procedure itself, that’s something to pay attention to. If there’s no clear timeline for evaluation, or no defined way to measure progress, that can make it difficult to assess outcomes. And if communication drops off after treatment, patients may be left without guidance during a process that is still unfolding. Regenerative medicine is not a one-time event. It’s a process that requires observation and, in some cases, adjustment. So what should patients expect? A comprehensive approach to stem cell therapy should include a clearly defined follow-up plan. You should know when you’ll be evaluated. What will be measured. And how your progress will be interpreted. There should be ongoing communication. Guidance on recovery and activity. And a structured way to track how you’re doing over time. It’s also reasonable to ask these questions before treatment begins. How often will I be seen after the procedure? What outcomes are you tracking? And how will decisions be made if adjustments are needed? Because ultimately, follow-up is about continuity. It connects the procedure to the outcome. And it helps ensure that what was done during treatment translates into meaningful, lasting results. Stem cell therapy is often discussed as a single event. But in reality, it’s a process that unfolds over weeks and months. And without structured follow-up, it’s difficult to fully understand that process or maximize its potential. When patients understand this, they’re better equipped to evaluate care, ask the right questions, and make more informed decisions.